Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2012; 18(14): 1642-1651
Published online Apr 14, 2012. doi: 10.3748/wjg.v18.i14.1642
Published online Apr 14, 2012. doi: 10.3748/wjg.v18.i14.1642
Table 2 Characteristics of the included studies
Study | Country | Type of study | Age, yr (mean ± SD) | Confirmation of HCV | Confirmation of T2D |
Akbar et al[40] | Saudi Arabia | CC | 94% had > 402 | Anti-HCV | FBS |
Antonelli et al[41] | Italy | CC | 65 ± 10 | Anti-HCV, HCV RNA | FPG |
Arao et al[42] | Japan | CC | Anti-HCV, HCV RNA | Random, FBG | |
Boschi-Pinto et al[43] | Japan | Cohort | 65% had > 542 | Anti-HCV | Nil |
Butt et al[44] | United States | Cohort | 50.82 | ICD-9 | |
Caronia et al[45] | Italy | CC | 57.5 ± 8 | Anti-HCV | FPG |
Chehadeh et al[8] | Kuwait | Cohort | 51 (23-73)3 | HCV RNA | FPG |
Chen et al[46] | Taiwan | CS | Anti-HCV | ||
Gulcan et al[47] | Turkey | CC | 56.89 ± 11.9 | Anti-HCV, HCV RNA | Guideline5 |
Howard et al[48] | United States | CS | 51 (37-75)3 | Anti-HCV, HCV RNA | Patient reported, FPG |
Huang et al[49] | Taiwan | CC | 52.7 ± 0.73 | Anti-HCV, HCV RNA | FPG |
Imazeki et al[50] | Japan | CC | 45 ± 16.5 | Anti-HCV, HCV RNA | FBS |
Jadoon et al[51] | Nigeria | Cohort | 48.19 ± 10.32 | Anti-HCV | Clinic diagnosed |
Kaabia et al[52] | Tunisia | CS | 55.62 | Anti-HCV, HCV RNA | Patient reported |
Knobler et al[53] | Israel | CC | 54 ± 14 | HCV RNA | FPG |
Lecube et al[54] | Spain | Cohort | 52.9 ± 14.1 | Anti-HCV, HCV RNA | FPG |
Li-Ng et al[55] | United States | Cohort | 30-794 | HbsAg1 | ICD-9 |
Mason et al[5] | United States | CS | 72% had > 37 | Anti-HCV | FPG, Random |
Marzouk et al[56] | Egypt | Cohort | > 252 | Anti-HCV, HCV RNA | FBS |
Mehta et al[57] | United States | CS | > 202 | Anti-HCV | FPG |
Nwokediuko et al[58] | Nigeria | CS | 55.8 ± 11.84 | Anti-HCV | FPG |
Okan et al[59] | Turkey | CS | 51.92 | Anti-HCV, HCV RNA | Nil |
Olokoba et al[60] | Nigeria | CS | 51.5 ± 12 | Anti-HCV | FBS |
Papatheodoridis et al[7] | Greece | Cohort | 48.1 ± 15.3 | Anti-HCV, HCV RNA | FPG |
Qureshi et al[61] | Pakistan | CS | 42 ± 13 | Anti-HCV | Random |
Rouabhia et al[62] | Pakistan | CS | 55 ± 9 | Anti-HCV, HCV RNA | FPG |
Ryu et al[63] | Korea | Cohort | 44 ± 14 | Anti-HCV | FPG |
Sangiorgio et al[64] | Italy | CS | Anti-HCV | ||
Simó et al[65] | Spain | CC | 46.4 ± 21.2 | Anti-HCV | WHO |
Wang et al[66] | Taiwan | Cohort | 50.9 ± 14.2 | Anti-HCV | FPG |
Wang et al[67] | China | CC | 50.9 ± 14.2 | HCV RNA | FBS |
- Citation: Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. World J Gastroenterol 2012; 18(14): 1642-1651
- URL: https://www.wjgnet.com/1007-9327/full/v18/i14/1642.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i14.1642